lunes, 17 de octubre de 2016

Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014

Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014

Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People



 PCD logo



Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014

Victoria L. Wagner, MS; Wei Jing, MS; Francis P. Boscoe, PhD; Maria J. Schymura, PhD; Patrick J. Roohan, MS; Foster C. Gesten, MD

Suggested citation for this article: Wagner VL, Jing W, Boscoe FP, Schymura MJ, Roohan PJ, Gesten FC. Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014. Prev Chronic Dis 2016;13:160185. DOI: http://dx.doi.org/10.5888/pcd13.160185.
PEER REVIEWED

Abstract

Introduction
In 2010, national guidelines recommended that women with nonmetastatic, hormone receptor–positive breast cancer take adjuvant hormone therapy for 5 years. As results from randomized clinical trials became available, guidelines were revised in 2014 to recommend 10 years of therapy. Despite evidence of its efficacy, low initiation rates have been documented among women insured by New York State Medicaid. This article describes a coordinated quality improvement pilot conducted by a state department of health and Medicaid managed care plans to engage women in guideline-concordant adjuvant hormone therapy.
Methods
Women enrolled in Medicaid managed care with nonmetastatic, hormone receptor–positive breast cancer and who had surgery from May 1, 2012, through November 30, 2012, were identified using linked Medicaid and Cancer Registry data. Adjuvant hormone therapy status was determined from Medicaid pharmacy data. Contact information for nonadherent women was supplied to health plan care managers who conducted outreach activities. Adjuvant hormone therapy status in the 6 months following outreach was evaluated.
Results
In the 6 months postoutreach, 61% of women in the contacted group filled at least 1 prescription, compared with 52% in the noncontacted group. Among those with at least 1 filled prescription, 50% of the contacted group were adherent, compared with 25% in the noncontacted group.
Conclusion
This pilot suggests outreach conducted by health plan care managers, facilitated by linked Medicaid and Cancer Registry data, is an effective method to improve adjuvant hormone therapy initiation and adherence rates in Medicaid managed care–insured women.
 Top

Introduction

Breast cancer is the most commonly diagnosed cancer in women in the United States and has the second highest death rate (1–5). In 2013 in New York State (NYS), 15,680 women were diagnosed with breast cancer, and 2,576 died (6). Roughly 70% of breast cancers are hormone receptor positive (HR-positive) (ie, the tumor’s growth is promoted by estrogen, progesterone, or both) (7,8). Adjuvant hormone therapy (AHT) works either by lowering hormone levels or blocking the action of hormone on tumor cells, and it reduces annual recurrence rates by approximately 40% as well as improves survival rates (9–11). Because results from randomized clinical trials demonstrate additional benefits from longer courses of treatment, national guidelines in 2014 recommended extending the use of AHT for women with nonmetastatic, HR-positive breast cancer from the previously recommended 2010 guideline of 5 years to 10 years, starting within a year of diagnosis (12). Despite this change in recommendation, suboptimal use of AHT is documented, particularly among low-income, minority, and young women (13–18).
NYS has one of the largest Medicaid programs in the country, serving a low-income, largely minority population. In 2013, more than 5.3 million New Yorkers were insured by Medicaid (19). Previous investigation into AHT use in NYS’s Medicaid population indicated that just 68% of women diagnosed from 2004 through 2006 initiated AHT within 1 year of diagnosis, and 58% of women who initiated AHT were adherent in the following year (20). These findings are consistent with those of previous studies (13,21).
Given the need to improve AHT use by NYS Medicaid-insured women and the ability to identify those who are not receiving AHT by linking their Medicaid data with NYS Cancer Registry (NYSCR) data, the NYS Department of Health implemented a quality improvement pilot. This article describes the coordinated, quality-improvement pilot conducted to engage women in guideline-concordant AHT care.
 Top

Methods

Population

NYS Medicaid encounter data (ie, health service use data submitted by managed care plans) as well as Medicaid claim and eligibility data were used to identify women aged 21 to 64 years with a breast cancer surgery (captured using breast cancer diagnosis codes in conjunction with surgical procedure codes) in the 7 month period from May through November 2012. Because this pilot was designed to target women with newly diagnosed breast cancer, women with a breast cancer surgery in the preceding 5 years were eliminated from the cohort. Medicaid data on breast cancer surgery were then linked to NYSCR data to confirm the breast cancer diagnosis and to extract information on stage of disease (local, regional, or metastatic) and tumor HR status. The cohort was further restricted to exclude women who were also Medicare beneficiaries (called “dual-eligibles”) because Medicare pharmacy data were not available. The final cohort comprised women with nonmetastatic, HR-positive breast cancer who were enrolled in one of 8 Medicaid managed care (MMC) plans that volunteered to participate in the pilot. This cohort represented approximately half (8 of 17) of the mainstream MMC plans in NYS and covered all regions of the state.
NYS Medicaid pharmacy encounter data were used to determine AHT status. Women captured in 1 of the following 3 groups were considered eligible for outreach: AHT noninitiated, women with no filled AHT prescriptions from April 2012 through the date of the data pull (August 7, 2013); AHT nonadherent, women with a medication possession ratio of less than 0.8 (sum of days’ supply divided by the difference between last and first fill dates); and AHT discontinued, women with no filled prescriptions from April 2013 through the data pull. We also stratified data according to race/ethnicity (white, Hispanic, black, Asian/Pacific Islander, or Native American/other/unknown) and region of residence (New York City or elsewhere in NYS).

Outreach

Written outreach materials were developed collaboratively with health plans and available to care managers in both English and Spanish (Appendix). Before commencing telephone outreach to patients, health plans sent letters to patients’ physicians (preferably oncologists if one was identified in encounter data). Physician letters had a dual-purpose; they were sent as a courtesy to notify physicians that the health plans would be contacting their patients, and they also requested that physicians contact health plan staff if a patient should not be called because of extenuating circumstances. After the physician letters were sent, health plans sent letters to patients informing them that a representative from the health plan would be calling to discuss their recent treatment for breast cancer. Health plan care managers made up to 5 attempts to contact each patient by telephone. To guide their conversation with patients, care managers used a telephone script that addressed current guidelines for AHT use, provided assurance that the cost of AHT was covered by health plans, and offered to help women talk with their doctors about AHT.
To facilitate outreach, the following information was extracted from Medicaid data systems and supplied to health plans: patient name, address, telephone number, date of birth, and AHT status; oncologists’ National Provider Identifier code; and an indicator to identify Spanish-speaking women. A web-based data exchange platform was used to securely transfer data to health plan staff and collect information on contact attempts, including outreach completion status and date.
For the analyses, we defined 3 groups: 1) women who met our inclusion criteria but who were AHT adherent at the start of activities, 2) women who were contacted and completed the telephone script with care managers, and 3) women whom care managers were unable to contact or who refused to complete all components of the telephone script.
Ideally, the evaluation period would commence on the date that outreach was completed; however, because of variation in health plan roll-out of pilot activities and challenges contacting women, outreach completion dates ranged from September through November 2013. Additionally, although health plan care managers submitted outreach completion dates via the web-based data exchange platform for women contacted by telephone, a similar intervention start date was not available for the 2 control groups (those who were AHT adherent and those who were not contacted). To compare the 3 groups, the median outreach completion date (September 25, 2013) was used as the standard start date for evaluating AHT outcomes for all 3 groups. To validate our results, we compared 2 sets of analyses, 1 using the actual outreach completion date and the other using the median outreach completion date. Results were the same (data not shown), suggesting that this was an appropriate approach.

Outcome assessment and statistical analysis

NYS Medicaid data were used to identify AHT prescriptions filled within 6 months of the median outreach completion date. The proportion of women with at least 1 filled AHT prescription after September 25, 2013, was calculated. The AHT possession ratio was also calculated as the sum of days’ supply of AHT prescriptions from September 25, 2013, through March 23, 2014, divided by 180. Women were considered AHT adherent if the AHT possession ratio was greater than or equal to 0.8.
Fisher’s exact and χ2 tests were used to assess significance in demographic distributions between contacted and noncontacted groups. One-tailed t tests and 1-tailed Fisher’s exact tests were used to determine significant differences in AHT use postintervention. Analyses were performed using SAS 9.4 and SAS Enterprise Guide 6.1 (SAS Institute, Inc). Significance was set at P < .05. This project was granted exempt status by the New York State Department of Health’s institutional review board.
 Top

Results

A total of 1,614 women who had breast cancer surgery from May 1, 2012, through November 30, 2012, were identified. Among these women, 255 were aged 21 to 64 years, were not dual-eligible, had been diagnosed with nonmetastatic, HR-positive breast cancer, and were enrolled in a participating health plan as of July 2013. Within this cohort, 81 (32%) women required outreach; their AHT status before outreach was as follows: 46 (57%) were AHT noninitiated, 19 (23%) were AHT nonadherent, and 16 (20%) were AHT discontinued. The remaining 174 women (68%) were AHT adherent and were not targeted for outreach.
Of the 81 women identified for outreach, 3 (4%) women were disenrolled from MMC between the release of data and the start of outreach activities, 42 (52%) were successfully contacted by telephone, and 36 (44%) could not be reached by telephone or did not complete the telephone script. As of March 2014, 163 (94%) of the AHT adherent group, 31 (86%) of the noncontacted group, and 36 (86%) women contacted were still enrolled in NYS MMC as non–dual-eligible.
Race/ethnicity proportions did not differ significantly (P = .87), with more than one-third of the women in each group white (Table 1). Among women in the contacted group, 47% were aged 50 to 64 years, whereas 68% were in the noncontacted group; however, the difference was not significant (P = .16). Most women in both groups resided in New York City (P = .89). No difference in proportion between the groups was noted with respect to stage of disease; most women in both groups had localized breast cancer (P = .89). The AHT adherent group served as a positive control for the adherence after the outreach, and data for this group are also presented (Table 1).
Among patients who were successfully contacted, 22 of 36 (61%) initiated AHT within 6 months of outreach (Table 2). This number was higher than for the group not successfully contacted; only 16 of 31 patients (52%) had initiated AHT. Among those with at least 1 filled AHT prescription, the contacted group had an average of 4.4 AHT prescriptions filled during the 6-month follow-up period, compared with 3.4 in the unable-to-contact group (data not shown). Although the adherence rate for the contacted group (50%) was not as high as that for the AHT adherent group (86%), it was higher than that for the nonadherent/noncontacted group (25%). Outreach status was marginally associated with adherence after outreach (P = .11).
We also compared the adherence rates in different subgroups (Table 3). Among women with a preoutreach status of AHT noninitiated who were contacted, 60% were adherent after outreach, compared with 37% in the noncontacted group. Higher adherence rates were observed among white, black and Asian/Pacific Islander women, as well as across all strata of age, region of residence, cancer stage, and preoutreach status.
 Top

Discussion

Nearly one third (32%) of MMC-insured women with nonmetastatic, HR-positive breast cancer were not AHT adherent and met our eligibility criteria. Results of the pilot suggest a benefit from health plan outreach, because women who were contacted were more likely to initiate and adhere to AHT, although the differences were not significant. Subpopulations such as white, black and Asian/Pacific Islander, as well as all strata of age group, region of residence, cancer stage and preoutreach status showed improvement in AHT adherence in the contacted group compared with the noncontacted group, suggesting that the outreach may be effective for diverse demographic groups. Among all races/ethnicities, Native American/other/unknown women had a high adherence rate before outreach (77.8%), as did Hispanic women (77.1%) (Table 1). These rates are comparable with rates reported in the literature of 70% to 85% (15,21–24). However, white and black women lagged behind with preoutreach AHT adherence rates of 60.7% and 65.2%, respectively. Given the observed disparities within our cohort of MMC-insured women, it makes sense that the greatest gains made by our outreach were among the groups with the lowest AHT adherence at baseline.
Our study has limitations. Medicaid pharmacy data indicate that a prescription was filled and picked up by the patient; it does not, however, indicate that the patient took the medication as prescribed. Also, this was a small-scale pilot, in which half of MMC plans participated. As such, the number of women included in the pilot and available for analysis was small. Because of our small study population, what appear to be meaningful differences between groups were not statistically significant. We did not conduct a randomized control trial; our testing and negative control groups were categorized on the basis of whether we could successfully contact them, which may have introduced bias between the 2 groups.
Although the number of breast cancers diagnosed in the NYS Medicaid population is small, this project (by encouraging MMC-insured women to initiate and adhere to AHT) has the potential to prevent cancer recurrence and save lives. For these reasons and based on the initial, positive findings presented here — in addition to the low cost of the project — the NYS Department of Health is moving forward to implement this pilot statewide in all mainstream MMC plans. Additionally, as NYS moves to develop an all-payer database (APD), the information contained within the APD would allow this project to expand and include Medicare and commercially insured women.
 Top

Acknowledgments

We thank the 8 health plans that participated in this pilot: Fidelis Care New York, Inc; Healthfirst PHSP, Inc; HealthPlus, an Amerigroup Company; HIP (EmblemHealth); Hudson Health Plan; MetroPlus Health Plan; MVP Health Care; and WellCare of New York.
 Top

Author Information

Corresponding Author: Victoria L. Wagner, MS, Office of Quality and Patient Safety, New York State Department of Health, ESP, Corning Tower, Room 1938, Albany, NY, 12237. Telephone: 518-486-9012. Email: victoria.wagner@health.ny.gov.
Author Affiliation: Wei Jing, Patrick J. Roohan, Foster C. Gesten, Office of Quality and Patient Safety, New York State Department of Health, Albany, New York; Francis P. Boscoe, Maria J. Schymura, New York State Cancer Registry, New York State Department of Health, Albany, New York.
 Top

References

  1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64(1):52–62. CrossRef PubMed
  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374–403. CrossRef PubMed
  3. Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 2015;26(4):779–86. CrossRef PubMed
  4. Zucchini G, Geuna E, Milani A, Aversa C, Martinello R, Montemurro F. Clinical utility of exemestane in the treatment of breast cancer. Int J Womens Health 2015;7:551–63. PubMed
  5. American Cancer Society. Cancer facts and figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed July 9, 2015.
  6. New York State Cancer Registry. Cancer incidence and mortality for New York State, 2009–2013. http://www.health.ny.gov/statistics/cancer/registry/vol1/v1rnys.htm. Accessed July 22, 2016.
  7. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 2015;12(10):573–83.CrossRef PubMed
  8. National Cancer Institute. Hormone therapy for breast cancer. http://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. Accessed December 28, 2015.
  9. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview. Ann Oncol 2006;17(Suppl 10):x59–62.CrossRef PubMed
  10. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451–67. CrossRef PubMed
  11. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 1989;7(6):803–15. PubMed
  12. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2014;32(21):2255–69. CrossRef PubMed
  13. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28(27):4120–8. CrossRef PubMed
  14. Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 2006;24(9):1357–62. CrossRefPubMed
  15. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21(4):602–6. CrossRef PubMed
  16. Komenaka IK, Martinez ME, Pennington RE Jr, Hsu CH, Clare SE, Thompson PA, et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst 2010;102(15):1178–87. CrossRef PubMed
  17. Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 2011;117(1):180–9. CrossRef PubMed
  18. Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 2009;27(13):2157–62. CrossRef PubMed
  19. New York State Department of Health. Number of Medicaid enrollees by category of eligibility by social service district — calendar year 2013. http://www.health.ny.gov/statistics/health_care/medicaid/eligible_expenditures/el2013/2013-cy_enrollees.htm. Accessed January 15, 2016.
  20. Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PJ, Boscoe FP, et al. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst 2012;104(14):1102–5. CrossRef PubMed
  21. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006;99(2):215–20. CrossRef PubMed
  22. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19(2):322–8. PubMed
  23. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol 2004;22(16):3309–15. CrossRef PubMed
  24. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007;109(5):832–9. CrossRef PubMed